RXRX RECURSION PHARMACEUTICALS, INC.
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1601830 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY56.2%
TTM net income YoY33.5%
TTM EPS YoY53.3%
Revenue 3-yr CAGR12.9%
Net income 3-yr CAGR—
Margins
Gross margin29.2%
Operating margin-725.4%
Net margin-697.1%
FCF margin-458.0%
EBITDA margin-617.2%
Returns
ROE-48.7%
ROA-36.3%
ROIC (approx.)-101.8%
Asset turnover0.05x
Leverage & solvency
Liabilities / assets25.9%
Debt / equity0.01x
Current ratio5.01x
Interest coverage-541.56x
Cash quality & payout
Operating cash flow / net income0.65x
Accruals ratio-12.6%
Payout ratio—
Capex / revenue2.9%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $74.68M | $58.84M |
| Cost of revenue | $70.95M | $45.24M |
| Gross profit | $3.73M | $13.60M |
| R&D expense | $475.27M | $314.42M |
| SG&A expense | $176.59M | $178.18M |
| Operating income | -$648.13M | -$479.00M |
| Interest expense | $1.81M | $1.57M |
| Pretax income | -$644.89M | -$464.79M |
| Income tax | -$136,000 | -$1.13M |
| Net income | -$644.76M | -$463.66M |
| EBITDA | -$564.43M | -$442.51M |
| EPS (basic) | -1.44 | -1.69 |
| EPS (diluted) | -1.44 | -1.69 |
| Weighted avg. shares (diluted) | 447.45M | 274.21M |
| Balance sheet | ||
| Cash & equivalents | $743.29M | $603.02M |
| Current assets | $812.85M | $714.27M |
| PP&E, net | $103.93M | $141.06M |
| Goodwill | $162.16M | $148.87M |
| Intangibles | $309.90M | $335.86M |
| Total assets | $1.47B | $1.45B |
| Current liabilities | $147.71M | $187.47M |
| Short-term debt | $9.09M | $8.43M |
| Long-term debt | $9.56M | $19.02M |
| Total debt | $18.66M | $27.45M |
| Total liabilities | $343.26M | $413.82M |
| Shareholders' equity | $1.13B | $1.03B |
| Net debt | -$724.64M | -$575.58M |
| Shares outstanding | 528.18M | 396.80M |
| Cash flow statement | ||
| Operating cash flow | -$371.81M | -$359.17M |
| Capital expenditure | $6.47M | $13.70M |
| Free cash flow | -$378.28M | -$372.87M |
| Investing cash flow | -$16.87M | $260.06M |
| Financing cash flow | $521.53M | $304.12M |
| Depreciation & amortization | $83.70M | $36.49M |
| Stock-based compensation | $111.22M | $81.69M |
Free plan shows the latest 2 periods; Pro shows all 7 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.